Global Healthcare Fund Reduces Stake in MBX Biosciences IPO

OrbiMed Advisors, a global healthcare investment firm, disclosed that it holds approximately 7.7% of MBX Biosciences, Inc. common stock, but noted that an increase in shares outstanding and some open-market sales have reduced its stake by more than one percentage point. OrbiMed said this holding is for portfolio investment purposes only, with no plans to participate in management, and that it may buy or sell shares in response to market conditions. It added that it continues to hold certain registration rights under its investor-rights agreement.

Recently, MBX Biosciences has been strengthening its infrastructure by signing a lease for new research and office space in Burlington, Massachusetts, effective February 2026. The company is also reorganizing its finance team, appointing an industry veteran as interim CFO after the current CFO’s departure in mid-March. The lease carries a total base rent of about $3.4 million, roughly 4.5 billion Korean won.

MBX Biosciences is a clinical-stage biotech company developing precision peptide therapeutics for endocrine and metabolic diseases. Its pipeline includes MBX 2109, a candidate for treating chronic hypoparathyroidism. In September 2024, the company raised approximately $160 million, or about 200 billion Korean won, through its Nasdaq IPO to fund its growth.